Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
LetterLetters to the Editor

Reply: Using and Interpreting 18F-FDG PET/CT Images in Patients Referred for Assessment of Cardiac Sarcoidosis: The Devil Is in the Details

David Birnie, Hiroshi Ohira and Rob Beanlands
Journal of Nuclear Medicine December 2017, 58 (12) 2040; DOI: https://doi.org/10.2967/jnumed.117.198226
David Birnie
*University of Ottawa Heart Institute 40 Ruskin St., Room H1285A Ottawa, K1S 2K4, Canada E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dbirnie@ottawaheart.ca
Hiroshi Ohira
*University of Ottawa Heart Institute 40 Ruskin St., Room H1285A Ottawa, K1S 2K4, Canada E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dbirnie@ottawaheart.ca
Rob Beanlands
*University of Ottawa Heart Institute 40 Ruskin St., Room H1285A Ottawa, K1S 2K4, Canada E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dbirnie@ottawaheart.ca
  • Article
  • Info & Metrics
  • PDF
Loading

REPLY: We thank Lu et al. for their comments. We certainly agree with many and, most importantly, that “Imaging of cardiac sarcoidosis remains challenging” for us all. To answer their specific points, first, regarding the duration of dietary preparation, our patients were recommended to consume two high-fat, low-carbohydrate meals, as is consistent with recent guidelines (1). We specifically choose not to exclude noncompliant patients because we wanted to challenge our readers with a spectrum of real-world cases.

Second, Yu et al. make a good point about correlating the 18F-FDG PET/CT results with the results of other types of imaging, such as cardiac MRI, and with clinical findings. We are looking at this in other ongoing projects and did not think it was needed for the main message of the current paper (2).

Third, regarding Figures 1 and 2, we did not screen the entire set of images but chose the first good examples identified. Also, the fact that Yu et al. do not agree with our image interpretation absolutely highlights the main message of our paper. For Figure 1B, Yu et al. correctly point out the issue of papillary muscle activity; however, the patient also clearly had basal anterior uptake and patchy right ventricular uptake consistent with the “focal on diffuse” pattern. Whether this pattern should be considered indeterminate for cardiac sarcoidosis is controversial. However, the recent SNMMI–ASNC expert consensus document (1) considered the “focal on diffuse” pattern to be consistent with possible inflammation. Further, the consensus document specifically highlights the importance of the location of the abnormal focal uptake in this situation (1). For Figure 2B, there is faint diffuse myocardial uptake; poor preparation may have contributed to this finding, but the lateral uptake intensity is in keeping with a normal variant (1,3,4).

Finally, we agree with the comment that it is possible that, with a modified patient preparation protocol (e.g., with 72 h of dietary preparation (5)), we might have achieved even greater interobserver agreement. However, the value, patient compliance with, and practically of very prolonged diet preparation have not been tested prospectively. Our work sets a standard against which subsequent research can be measured, and we very much hope that interreader variability can be greatly improved. Further research such as this is vitally important because clinicians caring for patients with cardiac sarcoidosis base important management decisions on 18F-FDG PET imaging results.

Footnotes

  • Published online Oct. 19, 2017.

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Chareonthaitawee P,
    2. Beanlands RS,
    3. Chen W,
    4. et al
    . Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med. 2017;58:1341–1353.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Ohira H,
    2. Mc Ardle B,
    3. deKemp RA,
    4. et al
    . Inter- and intra-observer agreement of 18F-FDG PET/CT image interpretation in patients referred for assessment of cardiac sarcoidosis. J Nucl Med. 2017;58:1324–1329.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Osborne MT,
    2. Hulten EA,
    3. Murthy VL,
    4. et al
    . Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol. 2017;24:86–99.
    OpenUrl
  4. 4.↵
    1. Morooka M,
    2. Moroi M,
    3. Uno K,
    4. et al
    . Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4:1.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Lu Y,
    2. Grant C,
    3. Xie K,
    4. Sweiss NJ
    . Suppression of myocardial 18F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. Clin Nucl Med. 2017;42:88–94.
    OpenUrl
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (12)
Journal of Nuclear Medicine
Vol. 58, Issue 12
December 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reply: Using and Interpreting 18F-FDG PET/CT Images in Patients Referred for Assessment of Cardiac Sarcoidosis: The Devil Is in the Details
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Reply: Using and Interpreting 18F-FDG PET/CT Images in Patients Referred for Assessment of Cardiac Sarcoidosis: The Devil Is in the Details
David Birnie, Hiroshi Ohira, Rob Beanlands
Journal of Nuclear Medicine Dec 2017, 58 (12) 2040; DOI: 10.2967/jnumed.117.198226

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Reply: Using and Interpreting 18F-FDG PET/CT Images in Patients Referred for Assessment of Cardiac Sarcoidosis: The Devil Is in the Details
David Birnie, Hiroshi Ohira, Rob Beanlands
Journal of Nuclear Medicine Dec 2017, 58 (12) 2040; DOI: 10.2967/jnumed.117.198226
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging
  • Google Scholar

More in this TOC Section

  • Business Model Beats Science and Logic: Dosimetry and Paucity of Its Use
  • Determining PSMA-617 Mass and Molar Activity in Pluvicto Doses
  • The Value of Functional PET in Quantifying Neurotransmitter Dynamics
Show more Letters to the Editor

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire